Skip to main content
Top
Published in: International Journal of Clinical Oncology 3/2008

01-06-2008 | Original Article

Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)

Authors: Toshirou Nishida, Kuniaki Shirao, Akira Sawaki, Masato Koseki, Takeshi Okamura, Atsushi Ohtsu, Toshiro Sugiyama, Kunihisa Miyakawa, Seiichi Hirota

Published in: International Journal of Clinical Oncology | Issue 3/2008

Login to get access
Metadata
Title
Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)
Authors
Toshirou Nishida
Kuniaki Shirao
Akira Sawaki
Masato Koseki
Takeshi Okamura
Atsushi Ohtsu
Toshiro Sugiyama
Kunihisa Miyakawa
Seiichi Hirota
Publication date
01-06-2008
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2008
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-007-0746-y

Other articles of this Issue 3/2008

International Journal of Clinical Oncology 3/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine